REG - Ergomed plc - Christopher Collins

ErgomedAnnouncement

11/03/2019 13:55

RNS Number : 4882S
Ergomed plc
11 March 2019
 


PRESS RELEASE
   FOR IMMEDIATE RELEASE
 
 
 
 
 
Christopher (Chris) Collins
 
 
Guildford, UK - 11 March 2019: The Directors of Ergomed plc are saddened to announce that Chris Collins, Non-executive Director, passed away on Friday 8 March 2019. The Board extends its deepest sympathies to Chris's family.
 
The Board wishes to acknowledge and express its gratitude for Chris's significant contribution to Ergomed since its IPO in July 2014.
 
 
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, commented:
 
"Chris played a key role in bringing Ergomed to the public market and has been a source of invaluable advice to the Board, based on his long career in the City.
 
"On behalf of everybody at Ergomed, I extend our sincerest condolences to Chris's family at this very sad and tragic loss."
 
-Ends-
 
 
Enquiries:
 




Ergomed plc


   Tel: +44 (0) 1483 402 975




Miroslav Reljanovic (Executive Chairman)


 




Stuart Jackson (Chief Financial Officer)


 




 


 




Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)


 




James Black (Joint Broker)


 




 


 




 


 




Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


 




 


 




MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke


 




 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUASORKBAOAAR